amylin glp-1 dual agonist Forget GLP-1: Wants to Be the Next Big Thing Targeting GLP-1, GIP & GCG

The tendencies in the timing of biomarker measurement were similar regardless of treatment, although metformin initiators had a higher probability of having their biomarker levels measured in general (Figure S8)

Imbernon M, Saponaro C, Helms HCC, Duquenne M, Fernandois D, Deligia E, et al

Further investigation is warranted to elucidate the neuroendocrine mechanisms underlying these interactions and to identify patient subgroups most likely to benefit from GLP-1based treatments

Under this deal, consumers buying injectable GLP-1 medications directly from these companies will pay $350 on average to begin with

The FDA has approved several GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)